About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
Formulary Substitution of Proton Pump Inhibitors Based on Acquisition Price: Changes in Usage and Costs of Acid-Suppressant Therapies
The authors discuss changes that occurred after three PPIs were removed from a hospital formulary and one less expensive, preferred PPI was added.
Robert MacLaren, PharmD, Tyree H. Kiser, PharmD, Rose Jung, PharmD, and Douglas N. Fish, PharmD
The authors review approaches for attention-deficit/hyperactivity disorder, mood disorders, bipolar disorder, mania, acute agitation, tic disorder or Tourette syndrome, binge-eating disorders, and the risk of suicidal behavior.
Lawrence M. Prescott, PhD, and Sharon L. Prescott
Standard and novel agents for various hematological malignancies include therapies for Hodgkinâ€™s lymphoma, chronic lymphocytic leukemia, acute and chronic myelogenous leukemia, myelodysplastic syndromes, and multiple myeloma.
Marvin M. Goldenberg, PhD, RPh, MS
COLD-fX, which differs from generic ginseng, affects both innate and acquired immune responses. The results of pivotal clinical trials are discussed.
Continuing Education Credit
For many years, attention-deficit/hyperactivity disorder was thought to affect only children and adolescents. The authors describe ADHD in adults and review the efficacy of the drugs prescribed for this population.
Joshua J. Gagne, PharmD, Madhusree Singh, MD, and Amy R. Talati, PharmD
Karl Matuszewski, MS, PharmD, discusses the need for hospitals to evaluate the cost-effectiveness of new technology.
Karl Matuszewski, MS, PharmD
Stephen Barlas discusses some upcoming bills for the new Congress on drug importation, Medicare Part D drug prices, and the FDAâ€™s role in approving generic biotechnology drug approvals and curbing the marketing of new drugs.
Matthew Grissinger, RPh, FASCP, reports on the confusion between epinephrine and ephedrine and offers strategies to reduce errors.
Matthew Grissinger, RPh, FASCP
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.
The authors review the clinical use of tipranavir (Aptivus) for HIV infection.
Angela Thornton, PharmD, Helen Y. Choy, PharmD, BCPS, Evans Branch III, PharmD, and Marlon Honeywell, PharmD